Discover 468 paid clinical trials in Grand Rapids, Michigan. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 468
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Location: Grand Rapids MI, Detroit MI, Rochester NY, Westwood KS,
Sponsor: Opna Bio LLC
Sex: All
Age: 18+
Code: NCT06433947
Phase 1, Recruiting
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
for
Advanced Breast Cancer
Location: Grand Rapids MI, Milwaukee WI, Chicago IL, Madison WI,
Sponsor: Stemline Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06638307
Phase 1, Recruiting
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
for
Advanced Solid Tumor
Location: Grand Rapids MI, Toronto, Rochester MN, St Louis MO,
Sponsor: Debiopharm International SA
Sex: All
Age: 12+
Code: NCT04855656
Phase 1, Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
for
HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer,
Location: Grand Rapids MI, Ann Arbor MI, Chicago IL, Detroit MI,
Sponsor: Iambic Therapeutics, Inc
Sex: All
Age: 18+
Code: NCT06253871
Phase 1, Recruiting
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
for
KRAS G12C Mutation, KRAS G12S Mutation,
Location: Grand Rapids MI, Cleveland OH, Rochester MN, Fairfax VA,
Sponsor: Kumquat Biosciences Inc.
Sex: All
Age: 18+
Code: NCT06720987
Phase 1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
for
Neoplasm, Cancer, Malignant Tumors
Location: Grand Rapids MI, Fairfax VA, Germantown TN,
Sponsor: Compugen Ltd
Sex: All
Age: 18+
Code: NCT06759649
Phase 1, Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
for
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma,
Location: Grand Rapids MI, Chicago IL, Detroit MI, Madison WI,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT06827236
Phase 1, Phase 2, Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
for
Head and Neck Squamous Cell Carcinoma (HNSCC),
Location: Grand Rapids MI, Columbus OH, Houston TX,
Sponsor: Tanabe Pharma America, Inc.
Sex: All
Age: 18+
Code: NCT06943521
Phase 1, Phase 2, Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
for
Acute Leukemia
Location: Grand Rapids MI, Milwaukee WI, Chicago IL,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 2+
Code: NCT04811560
Phase 1, Phase 2, Recruiting
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
for
Solid Tumor, Adult
Location: Grand Rapids MI, Fairfax VA, Middletown NJ, New York NY,
Sponsor: Effector Therapeutics
Sex: All
Age: 18+
Code: NCT04092673
Phase 1, Phase 2, Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Location: Grand Rapids MI, Philadelphia PA, Hackensack NJ,
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT05836324
Phase 1, Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
for
Colorectal Neoplasms
Location: Grand Rapids MI, Ann Arbor MI, Arlington Heights IL,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06662786
Phase 3, Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Location: Grand Rapids MI, Toledo OH, Appleton WI, Cleveland OH,
Sponsor: Guardant Health, Inc.
Sex: All
Age: 18+
Code: NCT05059444
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
for
Multiple Myeloma
Location: Grand Rapids MI, Ann Arbor MI, Novi MI, Chicago IL,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT05552222
Phase 3, Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
for
Colorectal Neoplasms
Location: Grand Rapids MI, Ann Arbor MI, Milwaukee WI,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06750094
Phase 3, Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
for
Uveal Melanoma
Location: Grand Rapids MI, Toronto, Rochester MN, Nashville TN,
Sponsor: IDEAYA Biosciences
Sex: All
Age: 18+
Code: NCT07015190
Phase 3, Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
for
HER2-positive Breast Cancer
Location: Grand Rapids MI, Toronto, Nashville TN, Ottawa,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07413939
Phase 2, Phase 3, Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
for
Metastatic Solid Tumor, Recurrent Solid Tumor,
Location: Grand Rapids MI, Chicago IL, Cleveland OH, St Louis MO,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06465069
Phase 1, Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
for
Limited-stage Small Cell Lung Cancer (LS-SCLC)
Location: Grand Rapids MI, Toledo OH, Bethesda MD, Orange City FL,
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Sex: All
Age: 18+
Code: NCT06095583
Phase 3, Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Grand Rapids MI, Zion IL, Detroit MI, Cleveland OH,